Skip to content

A Multi-center, Randomized, Independent Evaluator-Subject Blinded, Placebo-Controlled, Phase I/III Clinical Study to Evaluate Safety and Efficacy of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear

A Multi-center, Randomized, Independent Evaluator-Subject Blinded, Placebo-Controlled, Phase I/III Clinical Study to Evaluate Safety and Efficacy of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0003174
Enrollment
93
Registered
2018-09-11
Start date
2018-07-09
Completion date
Unknown
Last updated
2023-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Biological/Vaccine, Non-Stem Cell : Subjects undergo arthroscopic rotator cuff repair with or without autologous fibroblasts.

Sponsors

Tego Science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants must; Be 19 years of age or older. Require arthroscopic repair for full-thickness rotator cuff tear(>2cm, =5cm) assessed by MRI without improvement of symptoms despite more than 3 months of conservative management. Consent to undergo skin biopsy to manufacture test product. Understand fully the study and voluntarily sign the informed consent for participation in the study.

Exclusion criteria

Exclusion criteria: Participants with any of the following conditions will be excluded unless stated otherwise; Unsuitable for skin biopsy. Have additional subscapularis tear. Have prior medical history of the following at the time of screening. Operation of the affected shoulder Allergies to bovine proteins Anaphylaxis to gentamicin Coagulopathy Genetic disorders affecting fibroblasts or collagen (ex. achondroplasia, osteogenesis imperfecta) Malignant tumors within the last 5 years Have been diagnosed with any of the following diseases at the time of screening. Autoimmune disease (including RA) HIV Ab-positive Acute trauma, chronic shoulder dislocation, pyogenic infection on the affected shoulder Scapulohumeral osteoarthritis Be pregnant, breastfeeding, planning pregnancy or unwilling to use of contraceptives suggested in this study. Other surgical or nonsurgical procedures on the affected shoulder to be judged more appropriate than arthroscopic repair. Have participated in and received investigational agents in other clinical trials within 4 weeks of this study. Be deemed inadequate for the study by investigators.

Design outcomes

Primary

MeasureTime frame
Retear rate assessed an by independent evaluator with MRI

Secondary

MeasureTime frame
Change of ROM (Range of Motion);Changes of functional scores (Constant Score, ASES pain score and SST)

Countries

Korea, Republic of

Contacts

Public ContactJooHan Oh

Seoul National University Bundang Hospital

ojhysy@gmail.com+82-31-787-7197

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026